Published in Osteoporos Int on May 18, 2010
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures. Osteoporos Int (2011) 1.11
Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment. Osteoporos Int (2011) 1.00
Plasma concentrations of 25-hydroxyvitamin D among Jordanians: Effect of biological and habitual factors on vitamin D status. BMC Clin Pathol (2011) 0.99
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (2012) 0.91
Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol (2011) 0.91
Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int (2011) 0.89
Health technology assessment in osteoporosis. Calcif Tissue Int (2013) 0.85
Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital's fracture liaison service between January 2010 and December 2011. Osteoporos Int (2014) 0.83
Co-administration of aspirin and allogeneic adipose-derived stromal cells attenuates bone loss in ovariectomized rats through the anti-inflammatory and chemotactic abilities of aspirin. Stem Cell Res Ther (2015) 0.81
Managing osteoporosis in ulcerative colitis: something new? World J Gastroenterol (2014) 0.80
Exercise and fractures in postmenopausal women. Final results of the controlled Erlangen Fitness and Osteoporosis Prevention Study (EFOPS). Osteoporos Int (2015) 0.79
Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice. Tissue Eng Part A (2013) 0.78
Effect of twelve-month physical exercise program on patients with osteoporotic vertebral fractures: a randomized, controlled trial. Osteoporos Int (2016) 0.77
Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy. Clin Cases Miner Bone Metab (2012) 0.76
Bone health status in Indian women. Indian J Med Res (2013) 0.75
Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis. Exp Ther Med (2015) 0.75
Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.75
Dietary calcium intake and calcium supplementation in hungarian patients with osteoporosis. Int J Endocrinol (2013) 0.75
Systematic scoping review of patients' perceived needs of health services for osteoporosis. Osteoporos Int (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 9.86
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet (2007) 9.61
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med (1997) 6.88
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med (2009) 5.63
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Esophagitis associated with the use of alendronate. N Engl J Med (1996) 4.89
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma (2008) 3.74
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury (2008) 3.50
Mechanisms of anabolic therapies for osteoporosis. N Engl J Med (2007) 3.33
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int (2002) 2.82
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg (2009) 2.76
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr (2000) 2.68
Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med (1996) 2.66
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int (2006) 2.53
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med (1989) 2.43
Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone (2007) 2.33
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int (1992) 2.23
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol (2003) 2.16
Anabolic actions of parathyroid hormone on bone. Endocr Rev (1993) 2.13
Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab (2007) 2.11
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res (2004) 2.07
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA (1994) 2.03
Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology (2003) 2.01
Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res (2007) 1.97
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet (2003) 1.88
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin (2008) 1.79
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res (2001) 1.76
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res (2005) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab (2003) 1.65
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum (2008) 1.51
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics (2009) 1.45
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc (2004) 1.44
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.44
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int (2009) 1.39
The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone (1996) 1.38
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res (2005) 1.34
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone (2003) 1.34
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) (2010) 1.28
Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am (2008) 1.27
Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone (2007) 1.26
Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res (2006) 1.24
Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int (2006) 1.24
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
IOF position statement: vitamin D recommendations for older adults. Osteoporos Int (2010) 2.79
Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int (2012) 2.48
Interspecies differences in bone composition, density, and quality: potential implications for in vivo bone research. Endocrinology (1998) 2.24
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis (2004) 2.12
The sentinel node in breast cancer: acceptable false-negative rate. Lancet (1999) 2.06
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
Minimally invasive versus conventional aortic valve operations: a prospective study in 120 patients. Ann Thorac Surg (1999) 2.02
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int (2011) 1.77
Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab (2013) 1.77
Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab (2013) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) (2008) 1.71
Longitudinal study of the bone mineral content and of soft tissue composition after spinal cord section. Paraplegia (1995) 1.68
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
Assessment of the strength of proximal femur in vitro: relationship to femoral bone mineral density and femoral geometry. Bone (1997) 1.62
Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int (2004) 1.60
Chronic widespread pain is associated with slower cognitive processing speed in middle-aged and older European men. Pain (2010) 1.58
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. J Clin Endocrinol Metab (2013) 1.57
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin (2013) 1.55
Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. J Musculoskelet Neuronal Interact (2010) 1.53
Estradiol in elderly men. Aging Male (2002) 1.52
Breast cancer screening in the older woman: an effective way to reduce mortality? Maturitas (2010) 1.52
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
The role of activity in the therapeutic management of back pain. Report of the International Paris Task Force on Back Pain. Spine (Phila Pa 1976) (2000) 1.50
Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol (2001) 1.49
The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg Am (2001) 1.48
Serum inhibin B levels in community-dwelling elderly men. Clin Endocrinol (Oxf) (2000) 1.47
Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate. Pacing Clin Electrophysiol (1998) 1.46
Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol (1991) 1.45
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int (2009) 1.44
Testosterone, body composition and aging. J Endocrinol Invest (1999) 1.42
Fear-avoidance beliefs about back pain in patients with subacute low back pain. Pain (2006) 1.41
Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis (2013) 1.40
Calcitonin and bone mass status in congenital hypothyroidism. Calcif Tissue Int (1990) 1.39
Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos Int (2014) 1.39
Responsiveness to recombinant erythropoietin therapy in end-stage renal disease. An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors. Nephrol Dial Transplant (1992) 1.38
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone (2003) 1.34
Vitamin D inadequacy among post-menopausal women: a systematic review. QJM (2005) 1.34
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
Hip fracture and osteoporosis in a XIIth Dynasty female skeleton from Lisht, upper Egypt. J Bone Miner Res (1997) 1.31
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab (2003) 1.28
Ascorbate for the treatment of refractory idiopathic thrombocytopenic purpura. Br J Haematol (1990) 1.27
Screening for breast cancer with mammography. Lancet (2002) 1.27
Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab (2012) 1.26
Quality of sleep in patients with chronic low back pain: a case-control study. Eur Spine J (2008) 1.26
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Ann Rheum Dis (2013) 1.25
Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int (2006) 1.24
Upper and lower gastrointestinal evaluation of elderly inpatients who are iron deficient. Am J Med (1999) 1.23
Cesarean section scar evaluation by saline contrast sonohysterography. Ultrasound Obstet Gynecol (2004) 1.22
Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int (2012) 1.19
Validation of the French version of the Dallas Pain Questionnaire in chronic low back pain patients. Rev Rhum Engl Ed (1998) 1.19
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2010) 1.19
Costs and consequences of hip fracture occurrence in old age: an economic perspective. Disabil Rehabil (2005) 1.19
Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab (2007) 1.18
Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol (2013) 1.17
TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2009) 1.17
Silica-associated connective tissue disease. A study of 24 cases. Medicine (Baltimore) (1995) 1.16
Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. J Bone Miner Res (1997) 1.16
A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. J Rheumatol (1993) 1.15
Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis (2006) 1.14
Early adaptation of thyrotropin and thyroglobulin secretion to experimentally decreased iodine supply in man. Metabolism (1992) 1.14
Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 1.13
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J (2009) 1.12
Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium. QJM (2004) 1.12
Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab (1998) 1.11
Primary osteoarthritis of hip, knee, and hand in relation to occupational exposure. Occup Environ Med (2005) 1.11
Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis. Osteoarthritis Cartilage (2006) 1.11
Epidural corticosteroid injections for sciatica: a randomised, double blind, controlled clinical trial. Ann Rheum Dis (2003) 1.11
Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound. J Bone Miner Res (1997) 1.10
Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy--a prospective study. J Rheumatol (1993) 1.09
Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. J Musculoskelet Neuronal Interact (2014) 1.09
Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis (2008) 1.09
Tools in the assessment of sarcopenia. Calcif Tissue Int (2013) 1.09
Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage (2005) 1.08
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 1.07
The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas (2008) 1.07
The role of calcium and vitamin D in the management of osteoporosis. Bone (2007) 1.06
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract (2009) 1.06